| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Abemaciclib tabs |
08.01.05 |
Restricted Use
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abemaciclib tabs |
08.01.05 |
Restricted Use
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Adalimumab |
11.99.99.99 |
Restricted Use
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA146: Adalimumab for the treatment of adults with psoriasis |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adefovir Dipivoxil |
05.03.03.01 |
Restricted Use
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adenosine deaminase (ADA) cDNA sequence |
17 |
Non Formulary
|
NICE HST7: Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency |
| Afatinib |
08.01.05 |
Restricted Use
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Afatinib |
08.01.05 |
Restricted Use
|
NICE TA444 (not recommended): Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) |
| Aflibercept infusion |
08.01.05 |
Formulary
|
NICE TA307 (not recommended): Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept intraocular injection |
11.08.02 |
Restricted Use
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept intraocular injection |
11.08.02 |
Restricted Use
|
NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Aflibercept intraocular injection |
11.08.02 |
Restricted Use
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept intraocular injection |
11.08.02 |
Restricted Use
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Aflibercept intraocular injection |
11.08.02 |
Restricted Use
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
| Agomelatine |
04.03.04 |
Non Formulary
|
NICE TA231 (not recommended): Agomelatine for the treatment of major depressive episodes (terminated appraisal) |
| Alectinib tabs |
08.01.05 |
Formulary
|
NICE TA438 (not recommended): Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) |
| Alectinib tabs |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Restricted Use
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Alirocumab |
02.12 |
Restricted Use
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema |
| Alpelisib tabs |
08.01.05 |
Non Formulary
|
NICE TA652 (not recommended): Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (Terminated appraisal) |
| Alteplase |
02.10.02 |
Restricted Use
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Amantadine |
05.03.04 |
Restricted Use
|
NICE TA168 (amantadine NOT recommended): Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Amantadine |
05.03.04 |
Restricted Use
|
NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Anastrozole |
08.03.04.01 |
Restricted Use
|
NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Restricted Use
|
NICE TA156: Anti-D in pregnant women |
| Antithymocyte immunoglobulin - rabbit |
08.02.02 |
Restricted Use
|
NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults |
| Antithymocyte immunoglobulin - rabbit |
08.02.02 |
Restricted Use
|
NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people |
| Apixaban tabs |
02.08.02 |
Restricted Use
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apixaban tabs |
02.08.02 |
Restricted Use
|
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
| Apixaban tabs |
02.08.02 |
Restricted Use
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apremilast |
10.01.03 |
Restricted Use
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Restricted Use
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Aripiprazole |
04.02.01 |
Restricted Use
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Aripiprazole |
04.02.01 |
Restricted Use
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Arsenic Trioxide |
08.01.05 |
Non Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Asfotase alfa injection |
09.08.01 |
Non Formulary
|
NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia |
| Aspirin |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Ataluren granules |
10.02 |
Non Formulary
|
NICE HST3: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene |
| Atezolizumab inj |
08.01.05 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atezolizumab inj |
08.01.05 |
Formulary
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab inj |
08.01.05 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab inj |
08.01.05 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab inj |
08.01.05 |
Formulary
|
NICE TA618 (not recommended): Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) |
| Atezolizumab inj |
08.01.05 |
Formulary
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Atezolizumab inj |
08.01.05 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atomoxetine |
04.04 |
Restricted Use
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Autologous chondrocyte implantation using chondrosphere |
17 |
Non Formulary
|
NICE TA508: Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee |
| Avatrombopag tabs |
09.01.04 |
Restricted Use
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avelumab solution for infusion |
08.01.05 |
Restricted Use
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Avelumab solution for infusion |
08.01.05 |
Restricted Use
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Axicabtagene ciloleucel infusion |
08.01.05 |
Non Formulary
|
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
| Axitinib tabs |
08.01.05 |
Restricted Use
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
| Axitinib tabs |
08.01.05 |
Restricted Use
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Axitinib tabs |
08.01.05 |
Restricted Use
|
NICE TA650 (not recommended): Pembrolizumab with axitinib for untreated advanced renal cell carcinoma Technology appraisal guidance |
| Azacitidine |
08.01.03 |
Restricted Use
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Azacitidine |
08.01.03 |
Restricted Use
|
NICE TA399 (not recommended): Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Restricted Use
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Basiliximab |
08.02.02 |
Restricted Use
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Bee and Wasp Allergen Extracts |
03.04.02 |
Restricted Use
|
NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy |
| Belatacept |
08.02.02 |
Non Formulary
|
NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults |
| Belatacept |
08.02.02 |
Non Formulary
|
NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people |
| Belimumab |
10.01 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine infusion |
08.01.01 |
Restricted Use
|
NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |
| Bendamustine infusion |
08.01.01 |
Restricted Use
|
NICE TA206 (not recommended): Bendamustine for the treatment of indolent (low grade) non-Hodgkin’s lymphoma that is refractory to rituximab (terminated appraisal) |
| Bendamustine infusion |
08.01.01 |
Restricted Use
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Bendamustine infusion |
08.01.01 |
Restricted Use
|
NICE TA437 (terminated appraisal): Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) |
| Bendamustine infusion |
08.01.01 |
Restricted Use
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Benralizumab injection |
03.04.02 |
Restricted Use
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA263 (not recommended): Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA285 (not recommended): Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA214 (not recommended): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA284 (not recommended): Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA353 (not recommended): Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA436 (not recommended): Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA118 (not recommended): Bevacizumab for the treatment of metastatic colorectal cancer |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA148 (not recommended): Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA212 (not recommended): Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Bezlotoxumab |
14.05.02 |
Non Formulary
|
NICE TA601 (terminated appraisal): Bezlotoxumab for preventing recurrent Clostridium difficile infection |
| Binimetinib tabs |
08.01.05 |
Restricted Use
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Bivalirudin |
02.08.01 |
Restricted Use
|
NICE TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (STEMI) |
| Blinatumomab |
08.02.03 |
Non Formulary
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Blinatumomab |
08.02.03 |
Non Formulary
|
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: hepatitis |
| Bortezomib injection |
08.01.05 |
Restricted Use
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib injection |
08.01.05 |
Restricted Use
|
NICE TA129: Multiple myeloma - bortezomib |
| Bortezomib injection |
08.01.05 |
Restricted Use
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
| Bortezomib injection |
08.01.05 |
Restricted Use
|
NICE TA228: 1st line treatment of multiple myeloma |
| Bortezomib injection |
08.01.05 |
Restricted Use
|
NICE TA453 (not recommended): Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) |
| Bortezomib injection |
08.01.05 |
Restricted Use
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Bosutinib |
08.01.05 |
Restricted Use
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Bosutinib |
08.01.05 |
Restricted Use
|
NICE TA576 (not recommended): Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Botulinum toxin type A |
04.13 |
Non Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Brentuximab vedotin infusion |
08.01.05 |
Restricted Use
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin infusion |
08.01.05 |
Restricted Use
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brentuximab vedotin infusion |
08.01.05 |
Restricted Use
|
NICE TA594 (terminated appraisal): Brentuximab vedotin for untreated advanced Hodgkin lymphoma |
| Brentuximab vedotin infusion |
08.01.05 |
Restricted Use
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin infusion |
08.01.05 |
Restricted Use
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brigatinib tabs |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab |
13.05.03 |
Restricted Use
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Buprenorphine sublingual tablets |
04.10.03 |
Formulary
|
NICE TA114: Drug misuse - methadone and buprenorphine |
| Burosumab injection |
06.06.02 |
Non Formulary
|
NICE HST8: Burosumab for treating X-linked hypophosphataemia in children and young people |
| Cabazitaxel |
08.01.05 |
Restricted Use
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib caps |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Cabozantinib tabs |
08.01.05 |
Restricted Use
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib tabs |
08.01.05 |
Restricted Use
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Canakinumab |
10.01.04 |
Non Formulary
|
NICE TA281 (not recommended): Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) |
| Canakinumab |
10.01.04 |
Non Formulary
|
NICE TA302 (not recommended): Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) |
| Cangrelor |
02.09 |
Restricted Use
|
NICE TA351 (not recommended): Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) |
| Cannabidiol oral solution |
04.08.01 |
Non Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol oral solution |
04.08.01 |
Non Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Capecitabine and tegafur with uracil for metastatic colorectal cancer |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Carfilzomib |
08.01.05 |
Restricted Use
|
NICE TA457: Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine implant |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine implant |
08.01.01 |
Non Formulary
|
NICE TA149 (not recommended): Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) |
| Cemiplimab infusion |
08.01.05 |
Formulary
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
| Cenegermin 20micrograms/ml eye drops |
11.99.99.99 |
Non Formulary
|
NICE TA532 (not recommended): Cenegermin for treating neurotrophic keratitis |
| Ceritinib |
08.01.05 |
Restricted Use
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Restricted Use
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Cerliponase alfa |
09.08.01 |
Non Formulary
|
NICE HST12: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 |
| Certolizumab pegol |
13.05.03 |
Formulary
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Certolizumab pegol |
10.01.03 |
Restricted Use
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab pegol |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab pegol |
10.01.03 |
Restricted Use
|
NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA472: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Ciclosporin 0.1% eye drops |
11.99.99.99 |
Restricted Use
|
NICE TA369: Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Cilostazol |
02.06.04 |
Non Formulary
|
NICE TA223 (not recommended): Intermittent claudication drugs |
| Cinacalcet |
09.05.01.02 |
Restricted Use
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cladribine tablets |
08.02.04 |
Restricted Use
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414 (not recommended): Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Colistimethate inhaler |
05.01.07 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase injection |
10.03.01 |
Non Formulary
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Cytarabine–daunorubicin liposomal injection |
08.01.03 |
Non Formulary
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Dabigatran caps |
02.08.02 |
Restricted Use
|
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
| Dabigatran caps |
02.08.02 |
Restricted Use
|
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism (VTE) after hip or knee replacement surgery in adults |
| Dabigatran caps |
02.08.02 |
Restricted Use
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabrafenib caps |
08.01.05 |
Restricted Use
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Dabrafenib caps |
08.01.05 |
Restricted Use
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
| Dabrafenib caps |
08.01.05 |
Restricted Use
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Daclatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Daclizumab |
08.02.04 |
Restricted Use
|
NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dacomitinib tabs |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Daratumumab inj |
08.02.04 |
Restricted Use
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Daratumumab inj |
08.02.04 |
Restricted Use
|
NICE TA454 (not recommended): Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
| Daratumumab inj |
08.02.04 |
Restricted Use
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Daratumumab inj |
08.02.04 |
Restricted Use
|
NICE TA634 (not recommended): Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) |
| Darbepoetin alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Darvadstrocel injection |
01.05 |
Non Formulary
|
NICE TA556 (not recommended): Darvadstrocel for treating complex perianal fistulas in Crohn’s disease |
| Dasabuvir |
05.03.03.02 |
Restricted Use
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA241: CML where treatment with imatinib has failed |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270 (not recommended): Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) |
| Degarelix |
08.03.04.02 |
Restricted Use
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Restricted Use
|
NICE TA204: Osteoporotic fractures - denosumab |
| Denosumab |
06.06.02 |
Restricted Use
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamfetamine |
04.04 |
Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dimethyl fumarate |
13.05.03 |
Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dinutuximab beta injection |
08.02.04 |
Non Formulary
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
| Dipyridamole |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Docetaxel |
08.01.05 |
Restricted Use
|
NICE TA109: Breast cancer (early) - docetaxel |
| Docetaxel |
08.01.05 |
Restricted Use
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Donepezil |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Doxorubicin pegylated liposomal |
08.01.02 |
Restricted Use
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
| Dupilumab injection |
13.05.01 |
Restricted Use
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Dupilumab injection |
12.03.01 |
Non Formulary
|
NICE TA648 (not recommended): Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Eculizumab infusion |
04.13 |
Non Formulary
|
NICE TA647 (not recommended): Eculizumab for treating relapsing neuromyelitis optica (Terminated appraisal) |
| Eculizumab infusion |
04.13 |
Non Formulary
|
NICE TA636 (not recommended): Eculizumab for treating refractory myasthenia gravis (Terminated appraisal) |
| Eculizumab infusion |
09.01.03 |
Formulary
|
NICE HST1: Eculizumab for treating atypical haemolytic uraemic syndrome |
| Edoxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
| Edoxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Elbasvir + Grazoprevir |
05.03.03.02 |
Restricted Use
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eliglustat |
09.08.01 |
Formulary
|
NICE HST5: Eliglustat for treating type 1 Gaucher disease |
| Elosulfase alfa |
09.08.01 |
Restricted Use
|
NICE HST2: Elosulfase alfa for treating mucopolysaccharidosis type IVa (Morquio A Syndrome) |
| Elotuzumab |
08.01.05 |
Non Formulary
|
NICE TA434 (not recommended): Elotuzumab for previously treated multiple myeloma (terminated appraisal) |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA293: Eltrombopag for treating chronic ITP |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA382 (not recommended): Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) |
| Eluxadoline |
01.04.02 |
Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Encorafenib caps |
08.01.05 |
Restricted Use
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Entrectinib caps |
08.01.05 |
Restricted Use
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
| Entrectinib caps |
08.01.05 |
Restricted Use
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer |
| Epoetin alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin theta |
09.01.03 |
Non Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin zeta |
09.01.03 |
Non Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Eribulin |
08.01.05 |
Restricted Use
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Eribulin |
08.01.05 |
Restricted Use
|
NICE TA515 (not recommended): Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
| Erlotinib tab |
08.01.05 |
Restricted Use
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib tab |
08.01.05 |
Restricted Use
|
NICE TA227 (not recommended): Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
| Erlotinib tab |
08.01.05 |
Restricted Use
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib tab |
08.01.05 |
Restricted Use
|
NICE TA635 (not recommended): Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (Terminated appraisal) |
| Ertugliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Ertugliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
13.05.03 |
Restricted Use
|
NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis |
| Etanercept |
13.05.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etelcalcetide |
09.05.01.02 |
Restricted Use
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.02.02 |
Non Formulary
|
NICE TA348 (not recommended): Everolimus for preventing organ rejection in liver transplantation |
| Everolimus |
08.02.02 |
Non Formulary
|
NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults |
| Everolimus |
08.02.02 |
Non Formulary
|
NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Evolocumab |
02.12 |
Restricted Use
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Ex vivo expanded autologous human corneal epithelial cells containing stem cells |
17 |
Non Formulary
|
NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns |
| Exemestane |
08.03.04.01 |
Restricted Use
|
NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Ezetimibe |
02.12 |
Restricted Use
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Restricted Use
|
NICE TA164: Hyperuricaemia - febuxostat |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine |
08.01.03 |
Formulary
|
NICE TA119 (not recommended): Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia |
| Fludarabine |
08.01.03 |
Formulary
|
NICE TA29: Fludarabine for B-cell chronic lymphocytic leukaemia |
| Fludarabine |
08.01.03 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Fluocinolone acetonide intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| Fluocinolone acetonide intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone acetonide intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy |
| Fremanezumab inj |
04.07.04.02 |
Non Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA239 (not recommended): Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA503 (not recommended): Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA652 (not recommended): Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (Terminated appraisal) |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Galantamine |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Galantamine modified release |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA374 (not recommended): Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Pancreatic cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 (topotecan, trabectedin and gemcitabine NOT recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gemtuzumab ozogamicin injection |
08.02.03 |
Non Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Gilteritinib tabs |
08.01.05 |
Non Formulary
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Glasdegib tabs |
08.01.05 |
Non Formulary
|
NICE TA646 (not recommended): Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) |
| Glatiramer acetate |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glecaprevir + Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: psoriatic arthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
01.05.03 |
Restricted Use
|
NICE TA329: NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Ibandronic Acid 150mg tablets |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Ibandronic Acid IV injection |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA437 (not recommended): Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA452 (not recommended): Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA608 (terminated appraisal): Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia |
| Idelalisib tabs |
08.01.05 |
Restricted Use
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia |
| Idelalisib tabs |
08.01.05 |
Restricted Use
|
NICE TA328 (not recommended): Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) |
| Idelalisib tabs |
08.01.05 |
Restricted Use
|
NICE TA469 (not recommended): Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) |
| Idelalisib tabs |
08.01.05 |
Restricted Use
|
NICE TA604 (not recommended): Idelalisib for treating refractory follicular lymphoma |
| Imatinib tabs |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Imatinib tabs |
08.01.05 |
Restricted Use
|
NICE TA209 (not recommended): Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Imatinib tabs |
08.01.05 |
Restricted Use
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imatinib tabs |
08.01.05 |
Restricted Use
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib tabs |
08.01.05 |
Restricted Use
|
NICE TA425 (not recommended): Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib tabs |
08.01.05 |
Restricted Use
|
NICE TA70: Imatinib for chronic myeloid leukaemia |
| Infliximab |
13.05.03 |
Restricted Use
|
NICE TA134: Infliximab for the treatment of adults with psoriasis |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Inositol Nicotinate |
02.06.04 |
Non Formulary
|
NICE TA223 (not recommended): Intermittent claudication drugs |
| Inotersen injection |
16.01 |
Restricted Use
|
NICE HST9: Inotersen for treating hereditary transthyretin amyloidosis |
| Inotuzumab ozogamicin injection |
08.01.05 |
Non Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Interferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
| Interferon beta-1a |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1a |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1b |
08.02.04 |
Restricted Use
|
NICE TA527 (not recommended): Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1b |
08.02.04 |
Non Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Irinotecan Hydrochloride |
08.01.05 |
Restricted Use
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Irinotecan pegylated liposomal |
08.01.05 |
Non Formulary
|
NICE TA440 (not recommended): Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| Ivabradine |
02.06.03 |
Restricted Use
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab injection |
10.01.03 |
Restricted Use
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab injection |
13.05.03 |
Restricted Use
|
NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis |
| Lanadelumab injection |
03.04.03 |
Restricted Use
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Restricted Use
|
NICE TA257 (lapatinib not recommended): Lapatinib or trastuzumab in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Larotrectinib oral solution |
08.01.05 |
Non Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Larotrectinib oral solution test |
08.01.05 |
Non Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Ledipasvir + Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA603 (not recommended): Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA634 (not recommended): Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide caps |
08.02.04 |
Restricted Use
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenvatinib caps |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lenvatinib caps |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib caps |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506 (not recommended): Lesinurad for treating chronic hyperuricaemia in people with gout |
| Letermovir tabs |
05.03.02.02 |
Non Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Letrozole |
08.03.04.01 |
Formulary
|
NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Lorlatinib tabs |
08.01.05 |
Restricted Use
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Loxapine inhalation |
04.02.01 |
Non Formulary
|
NICE TA286 (not recommended): Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) |
| Lubiprostone |
01.06.07 |
Restricted Use
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398 (not recommended): Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lusutrombopag tabs |
09.01.04 |
Restricted Use
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Lutetium (177Lu) oxodotreotide injection |
08.01.05 |
Formulary
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
| Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
| Memantine |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Methadone |
04.10.03 |
Formulary
|
NICE TA114: Drug misuse - methadone and buprenorphine |
| Methylnaltrexone |
01.06.06 |
Non Formulary
|
NICE TA277 (not recommended): Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) |
| Methylnaltrexone |
01.06.06 |
Non Formulary
|
NICE TA468 (terminated appraisal): Methylnaltrexone bromide for treating opioid-induced constipation |
| Methylphenidate |
04.04 |
Non Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate Hydrochloride |
04.04 |
Non Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate Hydrochloride |
04.04 |
Non Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate hydrochloride |
04.04 |
Restricted Use
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate Hydrochloride |
04.04 |
Restricted Use
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate Hydrochloride |
04.04 |
Restricted Use
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate Hydrochloride |
04.04 |
Non Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate Hydrochloride MR |
04.04 |
Non Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Midostaurin |
08.01.05 |
Non Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Restricted Use
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Migalastat caps |
09.08.01 |
Restricted Use
|
NICE HST4: Migalastat for treating Fabry disease |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Modafinil |
04.04 |
Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Mycophenolate mofetil |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Mycophenolate sodium |
08.02.01 |
Restricted Use
|
NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults |
| Mycophenolate sodium |
08.02.01 |
Restricted Use
|
NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people |
| Naftidrofuryl oxalate |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naldemedine tabs |
01.06.06 |
Formulary
|
NICE TA651: Naldemedine for treating opioid-induced constipation |
| Nalmefene |
04.10.01 |
Non Formulary
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Restricted Use
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Naltrexone + Bupropion |
04.05.01 |
Non Formulary
|
NICE TA494 (not recommended): Naltrexone–bupropion for managing overweight and obesity |
| Natalizumab |
08.02.04 |
Restricted Use
|
NICE TA127: Multiple sclerosis - natalizumab |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411 (not recommended): Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Neratinib tabs |
08.01.05 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nintedanib |
03.11 |
Non Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
03.11 |
Restricted Use
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Nintedanib |
08.01.05 |
Restricted Use
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Niraparib caps |
08.01.05 |
Non Formulary
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA530 (not recommended): Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Nivolumab injection |
08.01.05 |
Restricted Use
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
| Nusinersen injection |
10.02 |
Non Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443 : Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Ocrelizumab injection |
08.02.04 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab injection |
08.02.04 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocriplasmin intravitreal injection |
11.08.02 |
Restricted Use
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.02.03 |
Restricted Use
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Ofatumumab |
08.02.03 |
Restricted Use
|
NICE TA202 (not recommended): Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab |
| Ofatumumab |
08.02.03 |
Restricted Use
|
NICE TA469 (not recommended): Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) |
| Ofatumumab |
08.02.03 |
Restricted Use
|
NICE TA470 (not recommended): Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) |
| Olaparib |
08.01.05 |
Restricted Use
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Olaparib |
08.01.05 |
Restricted Use
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Olaparib |
08.01.05 |
Restricted Use
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Olaratumab |
08.01.05 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278: Omalizumab for treating allergic asthma |
| Ombitasvir + paritaprevir + ritonavir |
05.03.03.02 |
Restricted Use
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Oseltamivir |
05.03.04 |
Restricted Use
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Oseltamivir |
05.03.04 |
Restricted Use
|
NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Osimertinib tab |
08.01.05 |
Restricted Use
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Osimertinib tab |
08.01.05 |
Restricted Use
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Osimertinib tab |
08.01.05 |
Restricted Use
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Osimertinib tab |
08.01.05 |
Restricted Use
|
NICE TA621 (not recommended): Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer Technology appraisal guidance |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA108 (not recommended): Paclitaxel for the adjuvant treatment of early node-positive breast cancer |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel - Albumin Bound Formulation, solution for infusion |
08.01.05 |
Restricted Use
|
NICE TA362 (not recommended): Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) |
| Paclitaxel - Albumin Bound Formulation, solution for infusion |
08.01.05 |
Restricted Use
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Paclitaxel - Albumin Bound Formulation, solution for infusion |
08.01.05 |
Restricted Use
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Padeliporfin injection |
08.03.04.02 |
Non Formulary
|
NICE TA546 (not recommended): Padeliporfin for untreated localised prostate cancer |
| Palbociclib cap |
08.01.05 |
Restricted Use
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Palbociclib cap |
08.01.05 |
Restricted Use
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Panitumumab |
08.01.05 |
Restricted Use
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panitumumab |
08.01.05 |
Restricted Use
|
NICE TA240 (not recommended): Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) |
| Panitumumab |
08.01.05 |
Restricted Use
|
NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy |
| Panobinostat |
08.01.05 |
Restricted Use
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer sorbitex calcium |
09.02.01.01 |
Restricted Use
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Patisiran infusion |
16.01 |
Restricted Use
|
NICE HST10: Patisiran for treating hereditary transthyretin amyloidosis |
| Pazopanib |
08.01.05 |
Restricted Use
|
NICE TA215: Pazopanib in renal cell cancer |
| Pegaspargase |
08.01.05 |
Restricted Use
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon Beta-1a inj |
08.02.04 |
Restricted Use
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegloticase |
10.01.04 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA650 (not recommended): Pembrolizumab with axitinib for untreated advanced renal cell carcinoma |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA190: Lung cancer (non-small-cell, maintenance) - pemetrexed |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA124 (not recommended): Pemetrexed for locally advanced or metastatic non-small-cell lung cancer |
| Pentosan polysulfate sodium caps |
07.04.03 |
Restricted Use
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Pentoxifylline |
02.06.04 |
Formulary
|
NICE TA223 (not recommended): Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
| Pertuzumab injection |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab injection |
08.01.05 |
Restricted Use
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pertuzumab injection |
08.01.05 |
Restricted Use
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pimecrolimus 1% cream |
13.05.03 |
Restricted Use
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Restricted Use
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy |
| Polatuzumab vedotin solution for infusion |
08.01.05 |
Non Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Pomalidomide |
08.02.04 |
Restricted Use
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Pomalidomide |
08.02.04 |
Restricted Use
|
NICE TA602 (terminated appraisal): Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ponatinib |
08.01.05 |
Restricted Use
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Restricted Use
|
NICE TA317: Acute coronary syndrome - prasugrel |
| Prucalopride |
01.06.07 |
Restricted Use
|
NICE TA211: Constipation (women) - prucalopride |
| Radium-223 dichloride |
08.03.04.02 |
Restricted Use
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene |
06.04.01.01 |
Restricted Use
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Raloxifene |
06.04.01.01 |
Restricted Use
|
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ramucirumab infusion |
08.01.05 |
Non Formulary
|
NICE TA403 (not recommended): Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ramucirumab infusion |
08.01.05 |
Non Formulary
|
NICE TA378 (not recommended): Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy |
| Ramucirumab infusion |
08.01.05 |
Non Formulary
|
NICE TA609 (not recommended): Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (Terminated appraisal) |
| Ramucirumab infusion |
08.01.05 |
Non Formulary
|
NICE TA635 (not recommended): Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (Terminated appraisal) |
| Ranibizumab intravitrial injection |
11.08.02 |
Restricted Use
|
NICE TA274: Ranibizumab for treating diabetic macular oedema |
| Ranibizumab intravitrial injection |
11.08.02 |
Restricted Use
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (wAMD) |
| Ranibizumab intravitrial injection |
11.08.02 |
Restricted Use
|
NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Ranibizumab intravitrial injection |
11.08.02 |
Restricted Use
|
NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
| Ranibizumab intravitrial injection |
11.08.02 |
Restricted Use
|
NICE TA637 (not recommended): Ranibizumab for treating diabetic retinopathy (Terminated appraisal) |
| Recombinant human parathyroid hormone |
06.06.01 |
Non Formulary
|
NICE TA625 (terminated appraisal): Recombinant human parathyroid hormone for treating hypoparathyroidism |
| Regorafenib tab |
08.01.05 |
Formulary
|
NICE TA334 (not recommended): Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) |
| Regorafenib tab |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib tab |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib tab |
08.01.05 |
Formulary
|
NICE TA514 (not recommended): Regorafenib for previously treated advanced hepatocellular carcinoma |
| Reslizumab |
03.04.02 |
Non Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.03.02 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.03.02 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.03.02 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.03.02 |
Restricted Use
|
NICE TA300: Hepatitis C - peginterferon alfa and ribavirin in children and young people |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Rifaximin |
05.01.07 |
Restricted Use
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Restricted Use
|
NICE TA20: Motor neurone disease - riluzole |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Rituximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rituximab |
10.01.03 |
Restricted Use
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Rivaroxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA265: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Rivaroxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivaroxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Rivaroxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban tabs |
02.08.02 |
Restricted Use
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivastigmine |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Restricted Use
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Rucaparib tabs |
08.01.05 |
Non Formulary
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Ruxolitinib |
08.01.05 |
Restricted Use
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Ruxolitinib |
08.01.05 |
Restricted Use
|
NICE TA356 (not recommended): Ruxolitinib for treating polycythaemia vera (terminated appraisal) |
| Sacubitril + valsartan |
02.05.05.02 |
Restricted Use
|
NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Sacubitril valsartan |
02.05.05.02 |
Non Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
10.01.03 |
Restricted Use
|
|
| Secukinumab |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
10.01.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Simeprevir |
05.03.03.02 |
Restricted Use
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Simeprevir |
05.03.03.02 |
Restricted Use
|
NICE TA361 (not recommended): Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people |
| Sodium zirconium suspension |
09.02.01.01 |
Restricted Use
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir + Velpatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Sofosbuvir + Velpatasvir + Voxilaprevir |
05.03.03.02 |
Restricted Use
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children |
| Sorafenib tabs |
08.01.05 |
Restricted Use
|
NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma |
| Sorafenib tabs |
08.01.05 |
Restricted Use
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sorafenib tabs |
08.01.05 |
Restricted Use
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sotagliflozin |
06.01.02.03 |
Non Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Restricted Use
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Restricted Use
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus modified release |
08.02.02 |
Formulary
|
NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus modified release |
08.02.02 |
Formulary
|
NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus modified release |
08.02.02 |
Formulary
|
NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus modified release |
08.02.02 |
Formulary
|
NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus ointment |
13.05.03 |
Restricted Use
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tadalafil (10mg, 20mg) |
07.04.05 |
Restricted Use
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) |
| Tadalafil (2.5mg, 5mg) |
07.04.05 |
Non Formulary
|
NICE TA273 (not recommended): Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) |
| Talimogene laherparepvec |
08.01.05 |
Restricted Use
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tamoxifen |
08.03.04.01 |
Formulary
|
NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: capecitabine and tegafur with uracil for metastatic colorectal cancer |
| Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Telbivudine |
05.03.03.01 |
Non Formulary
|
NICE TA154 (not recommended): Telbivudine for the treatment of chronic hepatitis B |
| Temozolomide |
08.01.05 |
Restricted Use
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Temozolomide |
08.01.05 |
Restricted Use
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA207 (not recommended): Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) |
| Tenofovir disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Teriflunomide |
08.02.04 |
Restricted Use
|
NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Teriflunomide |
08.02.04 |
Restricted Use
|
NICE TA303: Teriflunomide for relapsing remitting MS |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Thalidomide |
08.02.04 |
Restricted Use
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tisagenlecleucel cells dispersion for infusion |
08.01.05 |
Non Formulary
|
NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Tisagenlecleucel cells dispersion for infusion |
08.01.05 |
Non Formulary
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin inhaler |
05.01.04 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tofacitinib tabs |
01.05.03 |
Restricted Use
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib tabs |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib tabs |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tolvaptan |
06.05.02 |
Restricted Use
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA389 (not recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trabectedin |
08.01.05 |
Restricted Use
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Restricted Use
|
NICE TA389 (not recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib tabs |
08.01.05 |
Restricted Use
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Treosulfan |
08.01.01 |
Non Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Trifluridine + tipiracil |
08.01.03 |
Restricted Use
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Ustekinumab |
10.01.03 |
Restricted Use
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
13.05.03 |
Restricted Use
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Restricted Use
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |
| Ustekinumab |
13.05.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Vandetanib tabs |
08.01.05 |
Non Formulary
|
NICE TA550 (not recommended): Vandetanib for treating medullary thyroid cancer |
| Varenicline tabs |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vemurafenib |
08.01.05 |
Restricted Use
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Venetoclax tabs |
08.01.05 |
Restricted Use
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Venetoclax tabs |
08.01.05 |
Restricted Use
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Verteporfin |
11.08.02 |
Restricted Use
|
NICE TA68: Photodynamic therapy for age related macular degeneration |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272 (not recommended): Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vismodegib |
08.01.05 |
Restricted Use
|
NICE TA489 (not recommended): Vismodegib for treating basal cell carcinoma |
| Voretigene neparvovec subretinal injection |
11.99.99.99 |
Non Formulary
|
NICE HST11: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367: Vortioxetine for treating major depressive episodes |
| Zanamivir inhalation |
05.03.04 |
Restricted Use
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Zanamivir inhalation |
05.03.04 |
Restricted Use
|
NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Zoledronic Acid |
06.06.02 |
Restricted Use
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
